Uptravi (Selexipag) Patent Expiration, LOE Window & CMS Spending
Uptravi (Selexipag) by Johnson & Johnson: FDA Orange Book core substance LOE 2031-02-01 (last listed 2037-06-01), 2 AB generics, $287.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N207947 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2031-02-01 |
| Last Listed Patent or Exclusivity Date | 2037-06-01 |
| Orange Book Patents (*PED Extensions) | 12 patents (6 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $287.5M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $287.5M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.